Localised renal-cell carcinoma often recurs after treatment, usually leading to incurable disease. 1 The risk of recurrence is highly associated with clinical and pathological factors, such as TNM stage, performance status, and Fuhrman grade. However, outcomes for patients with similar clinical and pathological features still diff er signifi cantly. Improved predictors of recurrence of renalcell carcinoma are needed. 2, 3 Although several molecular markers of disease progression have been proposed, no biomarkers of recurrence risk have been well established. Germline DNA polymorphisms are particularly attractive biomarkers since they are present at the time of diagnosis and are not aff ected by the state of the disease or the timing of diagnosis. Single nucleotide polymorphisms (SNPs) are inherited germline DNA sequence variants. These variants occur throughout the entire genome, in both coding and non-coding regions, and can modify biological pathways.
Introduction
Localised renal-cell carcinoma often recurs after treatment, usually leading to incurable disease. 1 The risk of recurrence is highly associated with clinical and pathological factors, such as TNM stage, performance status, and Fuhrman grade. However, outcomes for patients with similar clinical and pathological features still diff er signifi cantly. Improved predictors of recurrence of renalcell carcinoma are needed. 2, 3 Although several molecular markers of disease progression have been proposed, no biomarkers of recurrence risk have been well established. Germline DNA polymorphisms are particularly attractive biomarkers since they are present at the time of diagnosis and are not aff ected by the state of the disease or the timing of diagnosis. Single nucleotide polymorphisms (SNPs) are inherited germline DNA sequence variants. These variants occur throughout the entire genome, in both coding and non-coding regions, and can modify biological pathways. 4 A genome-wide association study identifi ed SNPs in EPAS1 (also called HIF2a) and a complex genetic architecture that were associated with risk for renal-cell carcinoma. [5] [6] [7] [8] A follow-up study reported that a variant in 11q13.3 re modulates the binding and function of hypoxia inducible factor (HIF) at a previously undiscovered transcriptional enhancer of CCND1 (which codes for cyclin D1). The protective haplotype impairs binding of HIF-2, resulting in an allelic imbalance of cyclin D1 expression. implicated in renal-cell carcinoma and the likelihood of recurrence of renal-cell carcinoma after resection.
Methods

Participants
We enrolled patients into a discovery cohort and a validation cohort. We enrolled patients into the discovery cohort from the Clinical Research Information System database of the Dana-Farber/Harvard Cancer Center Kidney Cancer Program (Boston, MA, USA). This database-started in 2001-is designed to prospectively study patients diagnosed with localised renal-cell carcinoma undergoing treatment. All patients had histo logically proven renal-cell carcinoma and were reviewed by a genitourinary pathologist at Dana-Farber/Harvard Cancer Center. The database included patients' baseline clinical and pathological data and information about disease outcome, including date of recurrence, and date of death or last follow-up. Date of recurrence was classed as the date of fi rst diagnosis of local or distant recurrence, or diagnosis of contralateral renal-cell carcinoma by the treating physician recorded in patient charts. Patients were followed up prospectively in a routine schedule devised by the treating physician. We only included patients of European-American ancestry to ensure that participants had similar genetic backgrounds. Ancestry information was gathered from patients' charts. The fi rst patient was enrolled on Jan 18, 2002, and last patient enrolled on May 6, 2010. All patients provided written informed consent. Study of this cohort was approved by the Dana-Farber/Harvard Cancer Center institutional review board.
We also enrolled an independent validation cohort of 151 patients with localised renal-cell carcinoma from the Brigham and Women's Hospital (Boston, MA, USA) pathology department. Patients' clinical information was ascertained from medical records. Enrolment for this cohort was from Aug 28, 1991, to June 10, 2010. Study of this cohort was approved by the independent institutional review board under a diff erent protocol.
Procedures
In the discovery cohort we analysed several signalling pathways and key processes that have an important role in the pathogenesis and progression of renal-cell carcinoma. 70 genes were selected, including genes from the VHL/HIF/VEGF and PI3K/AKT/mTOR pathways, and genes involved in immune regulation, metab olism, and detoxifi cation. [14] [15] [16] [17] [18] [19] SNPs were selected from several genes, including regions 50 kb upstream and 50 kb downstream of each gene with the goal of capturing common genetic variation. We used the European-American ancestry population (CEU) of the HapMap database (release 21) for the selection of SNPs. A minimum allele frequency of at least 5% and a minimum pairwise correlation index (r²) of 80% were needed for each polymorphism to ensure an adequate coverage of the gene sequence and statistical power. 20 SNPs from previously published studies that were signifi cantly associated with risk of developing renal-cell carcinoma were also selected for genotyping. All eligible non-synonymous coding SNPs in the 70 selected genes were included in the analysis. In the validation cohort, only the top 12 SNPs showing potential association with recurrence-free survival (p<0·05) in the discovery cohort were assessed.
For the discovery cohort, we extracted DNA samples from peripheral blood mononuclear cell by QIAamp DNA Blood mini kit (Qiagen, Valencia, CA, USA). For the validation cohort, we extracted DNA from the normal kidney parenchyma tissue in formalin-fi xed paraffi nembedded blocks with DNeasy 96 Blood & Tissue Kit (Qiagen). Genotyping was done with the Sequenom iPlex Gold platform (Sequenom, San Diego, CA, USA) with MALDI-TOF. The staff who did the genotyping were masked to the patient's diagnosis. All SNP assays were combined into a 12 multiplex pool design, and all reactions were done in a 384 well format. Roughly 5% of duplicate samples were randomly selected and We only analysed SNPs that had passed quality checks. We usually excluded those with a genotyping success rate of less than 85% or with a signifi cant deviation from Hardy-Weinberg equilibrium. In the discovery cohort, 290 of 368 SNPs were successfully genotyped with an average rate of 97%.
The primary analysis endpoint was recurrence-free survival, defi ned as time from curative surgery to recurrence or death or censored at the last date at which the patient was known to be alive. Other endpoints were recurrence-free interval, defi ned as time from surgery to recurrence or censored at death before recurrence or last follow-up, and time from surgery to all-cause death or overall survival.
Statistical analysis
For the discovery cohort, we treated each SNP as a categorical variable-either a common homozygote, a rare homozygote, or a heterozygote. Rare homozygotes were combined with heterozygotes if the rare homozygote count was very low (using a cutoff of ten or frequency of 2·5% for a variant group) to ensure that the analysis (regression model) could properly estimate the coeffi cient for the association. We tested the association be tween recurrence-free survival and genotype with the log-rank test. We used the false-discovery rate measure q value with a cutoff less than 0·1 to adjust for multiple comparisons. 21 The q value represents the expected proportion of false-positive results when testing for signifi cance. We used a false discovery rate threshold of 0·1 on the basis of the REMARK guidelines, 22 which state that a very stringent criterion needs to be used if any biomarkers are to hold up in future studies.
Once we identifi ed a polymorphism on the basis of log-rank test and false-discovery rate, we estimated the distribution of recurrence-free survival stratifi ed by allelic status by the Kaplan-Meier method. We tested the association between the polymorphism and endpoints
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ECOG PS=Eastern Cooperative Oncology Group performance status. HR=hazard ratio. *Reference group. 23 We also used the Cox model to estimate hazard ratios (HRs) and 95% CI between the SNP variants. We tested associations between the SNP variants and clinical and pathological factors with the χ² test for categorical variables and the Wilcoxon (for two groups of polymorphisms; eg, homozygote plus heterozygote vs wild type) or KruskalWallis (for three groups of polymorphisms; eg, homozygote vs heterozygote vs wild type) tests for continuous variables.
All reported p values were two-sided. We calculated q values with R on the basis of the measured distribution of p values from the log-rank test for individual SNPs. The analyses were done with SAS (version 9.2) and R (version 2.10.1).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
We analysed 554 patients; 403 patients in the discovery cohort and 151 in the validation cohort. Most patients in the discovery cohort were men, had an ECOG performance status of 0, clinical stage I or II disease, and clear-cell histology, with a median follow-up of 43 months (IQR 26-64) since surgery (table 1) . By comparison, the validation cohort had more women and more patients with an ECOG performance status of 1 or more; median follow-up was 66 months (IQR 23-106). Other clinical characteristics were much the same in each cohort.
184 (46%) of 403 patients had recurrence or died in the discovery cohort; 167 patients had recurrence and 104 patients died during the follow-up period. 44 (29%) of 151 patients had recurrence or died in the validation cohort; 22 patients had recurrence and 35 died.
Consistent with previous reports of patients with localised renal-cell carcinoma, patients with advanced stage and high tumour grade had a high risk of recurrence in both cohorts (table 2) . 3 We successfully genotyped 290 SNPs in the discovery cohort but excluded fi ve from the analysis because they had only a single variant group in our AmericanEuropean population. 12 SNPs were associated with recurrence-free survival (log-rank test p<0·05; table 3). One synonymous coding poly morphism (rs11762213; 144G→A) located in exon 2 of MET was signifi cantly associated with re currence-free survival after adjusting for false discovery with the q value (univariate log-rank p<0·0001, q=0·027; fi gure). Table 3 shows the distribution of the rs11762213 variants; the minor allele frequency of the polymorphism rs11762213G→A was 5·3%, consistent with the frequency in the CEU population of the HapMap database. The baseline clinical and pathological characteristics of patients with diff erent variants of this polymorphism did not diff er signifi cantly (appendix).
We further analysed the association between rs11762213 poly morphisms and outcomes in the discovery cohort with a multivariable Cox See Online for appendix For the R package see http:// bioconductor.org/packages/ devel/bioc/html/qvalue.html 5-year recurrence-free survival was estimated to be 19% (95% CI 9-44) for patients with AA or AG variants and 46% (95% CI 40-53) for patients with GG. The association between recurrence-free interval and the polymorphism was much the same (table 4), with allele A being associated with an increased risk of recurrence. The association of overall survival with the polymorphism was not statistically signifi cant (table 4) .
In the validation cohort, patients with risk allele A had an increased risk of recurrence or death (table 4; p=0·048). The p value was only just signifi cant, with a wide 95% CI, which was probably a result of the small sample size and a low count in the variant comparison group (16 for AA or AG vs 132 for GG). The results for recurrence-free interval were consistent with those from the discovery cohort (appen dix). By contrast, the association between the genotype variants with one or two copies of the A allele and overall survival was signifi cant in the validation cohort. We used integrated discrimination improvement 24 to estimate the eff ect of including the rs11762213 poly morphism as a risk factor for prediction of recurrence. Mean predicted probability of recurrence improved by 4% (95% CI 1 to 8) at 3 years and 13% (95% CI -3% to 30%) at 8 years compared with the model that did not include rs11762213 as a covariate (appendix).
Discussion
Patients with one or two copies of the minor risk allele A of the SNP rs11762213 in exon 2 of MET (144G→A) had a higher risk of recurrence of renal-cell carcinoma than did patients without this high risk allele. In our multivariable analysis, the A allele was also statistically signifi cantly associated with overall survival in the validation cohort, but not in the discovery cohort, which might be because of the longer follow-up in the validation cohort, or possibly the use of targeted treat ment in the discovery cohort, which is more recent than the validation cohort. To our knowledge, this study is the fi rst to report an association between a germline single nucleotide polymorphism and an increased risk of recurrence in patients with localised renal-cell carcinoma (panel).
MET is an intriguing biomarker candidate gene. MET is the transmembrane tyrosine kinase receptor for the hepatocyte growth factor. Activating MET mutations in the tyrosine kinase domain have been identifi ed in patients with type 1 hereditary papillary renal-cell carcinoma. 25 MET expression and signalling is increased in tumour tissues of several cancers, including sporadic renal-cell carcinoma. 26 MET also plays a part in the pathogenesis of renal-cell carcinoma, usually cooperating with VEGFR to promote tumour growth. 27 Additionally, MET protein might act as a sensor of adverse microenvironments (ie, hypoxia), driving cell invasion and metastasis through activation of genes involved in blood coagulation. 28 Fine mapping will be necessary to identify the true causal allele, since rs11762213 might simply be correlated with other alleles. The true causal polymorphism in linkage disequilibrium with rs11762213 could have direct downstream eff ects. If the causal allele is synonymous or non-coding, it will not directly alter the downstream protein product. However, synonymous or non-coding single nucleotide polymorphims can aff ect protein abundance, structure, or function through various means: (1) changing mRNA structure and stability; (2) kinetics of transcription or translation; or (3) alternative splicing. 29 Additionally, functional analysis should be done to confi rm that MET is a target gene driving disease aggressiveness and to determine exactly how genotype aff ects the risk of recurrence or death. If inherited variation within MET does increase the risk of recurrence of renal-cell carcinoma, use of MET inhibitors in highrisk patients could be benefi cial. Drugs targeting MET in many advanced solid tumours-including metastatic renal-cell carcinoma-are being tested in clinical trials. 26 Our results are strengthened by several facts. First, we assessed a well-defi ned cohort of patients with European-American ancestry, making this the largest study of its kind. Second, all patients in the discovery cohort were followed up prospectively after treatment, and their clinical and pathological characteristics are similar to other cohorts of patients with renal-cell carcinoma. Third, we included a broad range of relevant genes on the basis of previously published work. Fourth, we adjusted for multiple comparisons, reducing the chance of false-positive results. Fifth, our results were still signifi cant after adjusting for clinical and pathological covariates. Finally, we reproduced our fi ndings in an independent, albeit smaller, cohort of patients with localised renal-cell carcinoma with DNA extracted from normal tissue of formalin-fi xed paraffi n-embedded samples. Such tissue has been shown to provide excellent quality and quantity DNA for genome-wide genotyping of germline DNA, suffi cient for both linkage and association analyses. 30 Of note, we recorded a deviation from Hardy-Weinberg equilibrium for rs11762213 in our discovery cohort caused by a higher than expected minor homozygote rate, even though the minor homozygote rate was only 1%. This diff erence has several potential causes including selection bias, since we only included patients with renalcell carcinoma with no control group. The deviation from the Hardy-Weinberg equilibrium is a limitation, and our results should be interpreted with caution-direct comparisons with other populations might not be appropriate. Additionally, it is important to note that the frequency of the A allele in our cohort was much the same as the expected frequency in the HapMap CEU database (5%) and in the CEU cohort in the 1000 genome project (4·85%).
Most other studies of germline polymorphisms and renal-cell carcinoma assessed associations between SNPs and the risk of developing cancer, rather than recurrence. [5] [6] [7] Most of the previously reported polymorphisms were included in our analysis but were not associated with risk of recurrence. We are not aware of previous germline studies of MET polymorphisms and cancer risk or prognosis.
Our study should be replicated in other populations and larger cohorts to further validate our fi ndings. If validated as a risk factor, the polymorphism could be incorporated into future prog nostic instruments, potentially aiding in the design of adjuvant clinical trials with MET inhibitors, and clinical management. Additionally, functional studies should be done to identify the biological mechanisms involved in this association. 
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